-
May 20, 2024 | 
clinicalleader.com | Kerry Leyden |Caroline Potts |Jim DiCesare |Oriol Serra
Webinar: Build Your Diversity Action Plan with AI and Patient InsightsJoin us May 29th to explore how to build an effective Diversity Plan including enrollment goals, their rationale, and how to meet them. We’ll highlight how to avoid the key barriers to diversity such as implementation factors, patient access & awareness, and infrastructure changes, and you’ll learn the intricacies of prioritizing trial designs to meet FDA compliance. Click here to learn more.
-
Apr 1, 2024 | 
clinicalleader.com | Jenifer Ngo Waldrop |Darshan Kulkarni |Kerry Leyden |Caroline Potts
Exploring Tokenism In Clinical Trials For Rare Disease PatientsWhile recent efforts promote diversity in clinical studies, the lack of enforcement and tokenistic approaches risk leaving minorities behind. Delve into the urgency of addressing this crisis and building inclusivity for a healthier future for all.
-
Jan 24, 2024 | 
clinicalleader.com | Gregory J Privitera |Stuart Redding |Kerry Leyden
YPrime unveils a transformative brand focused on ‘Solving for Certainty’ in clinical trials. Experience the reimagined brand and explore the solutions that transform clinical research at www.yprime.com. The 3 Big Downsides To DCTsExamine three overlapping categories of concern when it comes to decentralized clinical trials: consent and selection, user experience, and comfort and privacy.
-
Jan 22, 2024 | 
clinicalleader.com | Larry Ajuwon |Kerry Leyden |Caroline Potts |Devra Densmore
YPrime unveils a transformative brand focused on Solving for Certainty in clinical trials. Experience the reimagined brand and explore the solutions that transform clinical research at www.yprime.com. New Calculator Could Help Determine Costs And Fair CompensationPatients, sponsors, and other stakeholders could finally get help estimating patients' cost burdens thanks to the industry’s first open-access financial burden calculator. Will FDORA Impact My Clinical Research Practice?
-
Nov 15, 2023 | 
clinicalleader.com | Dan Schell |Monica Roy |Kerry Leyden
Bayer Launches Investigator-Sponsored Collaborative StudiesBayer added three Phase 3 trials to its MOONRAKER clinical development program for the study of Kerendia (finerenone) as a potential treatment for heart failure. Overall, the goal for the program is to enroll 15,000 participants.
-
Sep 20, 2023 | 
clinicalleader.com | Steve O’Keeffe |Adam Bloomfield |Kerry Leyden |Caroline Potts
Is Osteoarthritis Cure — ARPA-H NITRO — Rocket Fuel Or TNT? The U.S. federal government just unveiled a moonshot to fix osteoarthritis. Rumored to be funded at $1 billion and launched out of the new Advanced Research Project Agency for Health (ARPA-H), the Novel Innovations for Tissue Regeneration in Osteoarthritis, or NITRO program, plans to cure OA in five years. But can it be done?
-
Sep 13, 2023 | 
clinicalleader.com | Stuart Redding |Kerry Leyden |Estelle Haenel
Webinar: How To Overcome Data Challenges And Experience The Benefits Of DCTs - Guidance For Patients, Sites, And SponsorsJoin us to discover how a data-led approach and innovative intuitive integration tools are resulting in closer connections to patients, consistent data flows, and faster insights. Learn how to transform the way you customize data management activities during collection and curation of data for a DCT clinical trial! Click here to learn more.
-
Aug 10, 2023 | 
clinicalleader.com | Kerry Leyden |Caroline Potts
Article
| August 10, 2023
By Kerry Leyden and Caroline Potts, Medical Research Network
Running a clinical trial requires significant time, investment, and site staff resources. However, research sites across the industry increasingly lack the essential resources needed to complete trials. The entire drug development process can be negatively impacted when sites are overburdened.
-
Aug 1, 2023 | 
clinicalleader.com | Kerry Leyden |Caroline Potts
Article
| August 1, 2023
By Kerry Leyden and Caroline Potts, Medical Research Network
Across the pharmaceutical industry, clinical research sites face many challenges. Individual sites vary widely in size, available resources, therapeutic areas, and other factors. The support they need differs as widely as the sites themselves.
-
Jun 7, 2023 | 
clinicalleader.com | Kerry Leyden |Judson Chase |Felicity Grzemski
ISR Reports has been filling the need for higher-quality market research in the pharmaceutical industry for over 15 years. Utilizing a rigorous primary research methodology, ISR offers off-the-shelf reports, as well as unparalleled custom research services. Their website also hosts several free resources covering topics such as CDMO and CRO selection, clinical development, drug manufacturing, eClinical technology, decentralized trials, the cell and gene market, and more. Visit ISR's homepage here.
